Skip to content
value.today

Assertio Therapeutics

ASRTUnlisted company
$75 Mlast known market cap, Mar 2026 — no current value
Compare
World rank
—
no current market cap
Revenue
—
annual
Net income
—
Employees
—

About Assertio Therapeutics

Assertio Therapeutics, Inc. (formerly Depomed, Inc.) is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Assertio Therapeutics timeline

2 events, 1995–2018
  1. 1995
  2. 🏁
    · approximate
    Founded
  3. 2018
  4. 📉
    · approximate
    Delisted from Nasdaq

Events of Assertio Therapeutics from Wikidata. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Assertio Therapeutics

Acquisitions and changes
No longer listed: ticker ASRT is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

$0 M$87 M$173 M$260 M$347 M2020202120222023202420252026

World rank over time

▲ up 8,438 places since 2020
2020-01-01: #18825#18,82520202021-01-01: #21569#21,56920212022-01-07: #22146#22,14620222022-12-25: #18092#18,09220222023-07-30: #15474#15,47420232024-01-05: #21656#21,65620242026-03-08: #10387#10,3872026

Rank in USA: #3,695 (Jan 2020) · #4,183 (Jan 2021) · #4,246 (Jan 2022) · #3,683 (Dec 2022) · #3,138 (Jul 2023) · #3,722 (Jan 2024) · #2,026 (Mar 2026)

Mutual funds holding Assertio Therapeutics#

5 funds hold shares worth $1 M. Since their previous reports 4 added shares and 17 sold, selling $6 M net.
Mutual funds holding Assertio Therapeutics
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC33,898$1 M—<0.01%+1.8%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC11,355$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC9,478$0 M—<0.01%+10%May 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust3,885$0 M—<0.01%newMay 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC3,360$0 M—<0.01%+22%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Markets and events: Assertio Therapeutics#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-06-15
156,285
1 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2026-06-15 23:50 UTC, code D, resumed 04:00 UTC
  • 2026-05-13 11:55 UTC, code T3, resumed 12:20 UTC
  • 2025-12-24 21:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 1,890 shares at $23.50
  • : 19 shares at $23.47
  • : 19 shares at $23.48
  • : 52,403 shares at $23.44
  • : 3,878 shares at $23.47

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lobbying by Assertio Therapeutics#

$0 spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$0
#1,529 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
—
  • Health Issues1 report

Lobbying firms hired in 2025

Farragut Partners LLP

Assertio Therapeutics: lobbying spending by year
YearSpendingOwn lobbyistsReports
2025$0—1
2024$200 K—4
2023$100 K—2
2019$200 K—4
2018$70 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Assertio Holdings, Inc” and “Assertio Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Assertio Therapeutics🇺🇸$75 M———
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Mar 8, 2026 (last known)
Profile updated:
Nov 14, 2026

Figures from value.today research, Wikipedia.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Assertio Therapeutics? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Assertio Therapeutics's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Assertio Therapeutics? Suggest a correction